Liabilities Breakdown
29.6 Million
Total Liabilities
13.93 Million
Current Liabilities
18.03 Million
Liabilities Non Curr
Aldeyra rises slowly despite modest market slide
 | By Rifka Kats | Macroaxis Story |
This article will break down few interesting ideas for the current Aldeyra Therapeutics investors and investors who consider a position in the company. We will inspect if investors should continue to be optimistic for the company outlook. The entity current daily volatility is 6.97 percent, with a beta of 0.15 and an alpha of 1.36 over DOW. We estimate Aldeyra Therapeutics as currently undervalued. The real value is approaching 9.18 per share. We have analyzed and interpolated thirty-one available fundamental indicators for Aldeyra Therapeutics, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Aldeyra Therapeutics financials, including its number of shares shorted, book value per share, working capital, as well as the relationship between the cash and equivalents and number of employees . Given that Aldeyra Therapeutics has a price to earning of (4.44) X, we suggest you to validate Aldeyra Therapeutics prevailing market performance to make sure the company can sustain itself down the road. Use Aldeyra Therapeutics to enhance returns of your portfolios. The stock experiences a moderate upward volatility. Check odds of Aldeyra Therapeutics to be traded at $4.8 in 30 days.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Ellen Johnson
The firm currently holds 14.84 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. Aldeyra Therapeutics currently holds 14.84 M in liabilities with Debt to Equity (D/E) ratio of 0.34, which is about average as compared to similar companies. This firm has a current ratio of 12.58, suggesting that it is liquid enough and is able to pay its financial obligations when due. Aldeyra financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of Aldeyra, including all of Aldeyra's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Aldeyra assets, the company is considered highly leveraged. Understanding the composition and structure of overall Aldeyra debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.
Understanding Aldeyra Total Debt
Aldeyra liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. Aldeyra has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on Aldeyra balance sheet include debt obligations and money owed to different Aldeyra vendors, workers, and loan providers. Below is the chart of Aldeyra main long-term debt accounts currently reported on its balance sheet. You can use Aldeyra financial leverage analysis tool to get a better grip on understanding its financial positionHow important is Aldeyra's Liquidity
Aldeyra financial leverage refers to using borrowed capital as a funding source to finance Aldeyra ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Aldeyra financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Aldeyra's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Aldeyra's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Aldeyra's total debt and its cash.
Is Aldeyra valued reasonably by the market?
Aldeyra Therapeutics preserves 4.01 % of shares owned by insiders. Net Loss for the year was (55.07 M) with profit before overhead, payroll, taxes, and interest of 0. Aldeyra Therapeutics Average Assets is fairly stable at the moment. Also, Aldeyra Therapeutics Average Equity is fairly stable at the moment.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Aldeyra. Please refer to our Terms of Use for any information regarding our disclosure principles.